Saturday, 31 October 2026European Markets

HOTELS DE PARIS Stock Rises By 33% In The Last 21 Sessions

Loading stream...

the french hospitality company, hotels de paris (hdp.pa), listed on france's cac 40, has recently seen an impressive stock surge. the company, which trades under the ticker hdp.pa, has seen its shares take a significant leap by 33.33% over the course of 21 sessions, jumping from eur1.95 to a whopping eur2.60 as of monday afternoon 14:58 est. this comes as welcome news amidst a rather lackluster scene where the index experienced a slight dip of 0.02%, settling at eur7,313.57.

about les hotels de paris sa

les hotels de paris sa was established back in 1992. as the name suggests, the company is paris-based and has under its management a network of 19 hotels located predominantly within the city. despite its premium locations, the company posted trailing twelve-month eps loss at eur-0.64. the existence of such loss raises some eyebrows, suggesting the company may be grappling with profitability issues, most likely stemming from the interplay of operational challenges, sector-specific impediments, or broader economic issues.

stochastic oscillator analysis

the stochastic oscillator, a popular tool among traders and investors to gauge overbought and oversold conditions, reveals that the hdp.pa's stock is currently considered oversold (=20). this is an essential pointer for investors as it serves up an opportunity to watch out for any potential trend reversals. such reversals signal potential undervaluation in the market, an indicator that could swing in the favor of savvy investors.

varying volatility

over the last quarter, it has been noted that the stock has seen noteworthy volatility. intraday variation has been peaking at an average of 6.43%. week and month volatility likewise clocked in impressive numbers, reaching 1.31 and 7.07 respectively. however, high volatility might not always be palatable. it is particularly appealing to risk-takers, those who seek quick gains and can afford to take risks. conversely, those investors seeking stability and smaller returns over the shorter term could find such volatility less appealing.

the need for market vigilance

the stock market is synonymous with fluctuating prices and shifting trends. this fluctuating nature requires potential or current shareholders to stay well informed of these changes. due consideration must also be given to all risk factors before they decide to leap into the investment fray.

more news about hotels de paris (hdp.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com